Chronic Myeloid Leukemia After Chemoradiotherapy in a Patient with Non-Small Cell Lung Cancer

Basit Öğe Kaydı
dc.authoridSinan Demircioğlu: 0000-0003-1277-5105en_US
dc.authoridÖzlen Bektaş: 0000-0002-2670-022Xen_US
dc.authoridÖzcan Çeneli 0000-0003-2541-1335en_US
dc.authoridMehmet Artaç: 0000-0003-2335-3354en_US
dc.contributor.authorDemircioğlu, Sinan
dc.contributor.authorKorkmaz, Levent
dc.contributor.authorYılmaz, Seda
dc.contributor.authorBektaş, Özlen
dc.contributor.authorÇeneli, Özcan
dc.contributor.authorArtaç, Mehmet
dc.date.accessioned2020-01-18T21:02:44Z
dc.date.available2020-01-18T21:02:44Z
dc.date.issued2017
dc.departmentNEÜ, Meram Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Anabilim Dalıen_US
dc.descriptionWOS:000419586300008en_US
dc.description.abstractChronic myeloid leukemia(CML) is a myeloproliferative disease characterized by uncontrolled proliferation of mature and maturing granulocytes. Chronic myeloid leukemia accounts for approximately 15 to 20 percent of leukemias in adults. The incidence is 1-2/10000 per year.1-2 There is only one risk factor, which is ionized radiation.3 There are some publitions in the literature about CML development after chemotherapy and/or radiotherapy. Here we presented a case that CML occured after chemotherapy concurrent with radiotherapy in non-small cell lung cancer patient. Sixty year old man who has diagnosed inoperable lung adenocarcinoma in 2013. Carboplatin concurrent with radiotherapy was administered to him. After 2 years follow-up with no progression of disease, the level of leucocyte was started to increase. White blood cell level was 41700/ul, haemoglobin level was 14.3 g/dl and platelet level was 239000/ul. Peripheral blood smear suggested chronic myeloid leukemia. Bone marrow aspiration and biopsy was performed. The biopsy was supported chronic phase chronic myeloid leukemia. Cytogenetic analysis showed %95 translocation (9;22) in 20 metaphasis. BCR-ABL was detected as 60% IS. Sokal, Hasford and EUTOS risk score was calculated high. Imatinib therapy was started as 400 mg/day. Hematologic response was seen 2 weeks after imatinib treatment. After 3, 6, 12 months, BCR-ABL was detected as 27% IS, 1% IS, and 0.4 IS, respectively. The patient is still being followed as remission for both lung cancer and CML.
dc.identifier.citationDemircioğlu, S., Yılmaz, S., Bektaş, O., Çeneli, Ö., Korkmaz, L., Artaç, M. (2017). Chronic myeloid leukemia after chemoradiotherapy in a patient with non-small cell lung cancer. Uhod - Uluslararasi Hematoloji-Onkoloji Dergisi, 27, 4, 256-257.en_US
dc.identifier.endpage257en_US
dc.identifier.issn1306-133Xen_US
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage256en_US
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TWpjd056TXlNZz09/chronic-myeloid-leukemia-after-chemoradiotherapy-in-a-patient-with-non-small-cell-lung-cancer
dc.identifier.urihttps://hdl.handle.net/20.500.12452/1230
dc.identifier.volume27en_US
dc.identifier.wosWOS:000419586300008en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofUluslararası Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryDiğeren_US]
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleChronic Myeloid Leukemia After Chemoradiotherapy in a Patient with Non-Small Cell Lung Canceren_US
dc.typeLetteren_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Demircioğlu, Sinan.pdf
Boyut:
205.18 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/ Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu